With billions of dollars of RSV vaccine market, which pharmaceutical companies can seize the track ahead of time?

[pharmaceutical network industry trends] respiratory syncytial virus (RSV) is an important pathogen causing lower respiratory tract infection in infants, the elderly and patients with immune deficiency According to who epidemiological data, RSV infection is related to more than 33 million cases of acute lower respiratory tract infection, more than 3 million visits and more than 110000 deaths every year RSV infection is possible in all ages, but it is more dangerous in infants and the elderly RSV can cause pneumonia, bronchitis and other lower respiratory diseases It is infectious According to data, the number of children under 5 years old infected with RSV is 33 million every year, and the death toll is about 160000 The mortality rate of RSV infection in the elderly over 65 years old is 7.2 / 100000 per year Because the symptoms of RSV are difficult to distinguish from influenza or other respiratory infections, many patients with RSV infection may not get the correct diagnosis In the United States alone, RSV causes 177000 elderly hospitalizations each year, of which 14000 die The global direct economic burden caused by RSV is more than 80 billion US dollars every year Therefore, who has listed the development of RSV vaccine as one of the urgent problems to be solved Evaluatepharma, a professional consulting agency in the pharmaceutical market, released the Market Research Report "world preview 2018, outlook to 2024" in 2018, predicting five vaccines under development with commercial potential, two of which are RSV vaccines If successfully listed, its total sales in 2024 will reach US $2.5 billion Although RSV causes huge economic losses every year and seriously threatens human health, its work of developing RSV vaccine has been carried out since 1960s Because of the commercial risk of research and development, it is difficult to develop RSV vaccine At present, there is no certified effective vaccine on the market Recently, however, the news in the field of respiratory syncytial virus (RSV) vaccine research and development began to emerge intensively, which has become the focus of new drug research and development in the industry On September 4, Janssen, a subsidiary of Johnson & Johnson, announced that the U.S FDA has granted it a breakthrough vaccine therapy to prevent severe respiratory diseases caused by respiratory syncytial virus (RSV) in the elderly aged 60 and over This breakthrough therapy represents an important breakthrough in the prevention of RSV infection The breakthrough therapy is based on clinical data of RSV vaccine of Janssen company Compared with the existing standard nursing, the vaccine shows a clinically significant improvement At present, RSV vaccine is in the stage of 2B concept validation research, which mainly studies the safety and effectiveness of RSV vaccine in the elderly aged 65 and above Secondly, large pharmaceutical companies (such as Sanofi, GSK, Pfizer, Janssen, etc.) and biotechnology companies (such as Novavax, Bavarian Nordic) have launched a number of clinical trials Many new start-ups have also completed large-scale financing, such as icosavax (US $51 million) and meissa (US $30 million) In addition to foreign biopharmaceutical giants aiming at this huge market, domestic RSV infection drugs and vaccine enterprises are reluctant to give up AI diweixin, South China vaccine, Bovo biology, etc all started to code RSV vaccine research and development South China vaccine is planned to raise 50 million yuan for the phase I clinical research of RSV vaccine, the company's operation and R & D expenditure AI diweixin used Treg regulation technology to independently design and develop RSV vaccine bars13 for ved, successfully induced Treg cells with negative regulation ability, effectively controlled the pneumonia of ved in RSV, and its adjuvant design greatly improved the antibody level Recently, bars13 successfully completed phase I clinical trial in Australia The trial successfully reached the clinical end point of phase I, and laid a solid foundation for dose exploration, immune program optimization and international multi center confirmatory clinic of follow-up RSV vaccine target population (the elderly and infants) Since the 1960s, the research and development of RSV vaccine has been very difficult However, with the development of RSV etiology and structural biology, new research results are widely used in the design and development of vaccine The research of RSV vaccine has made great progress, and the success of research and development is just around the corner.